Stay updated on IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page’s IPD Sharing revision indicator was updated from v3.6.2 to v3.6.3, reflecting a small documentation update.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision: v3.6.2 is now displayed on the page, signaling a software or content update. The study details and available information remain the same.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention / Treatment header was changed to Intervention/Treatment. The footer revision label was updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check32 days agoChange DetectedA new Revision: v3.5.5 entry was added along with updated dates (2026-05-18, 2026-06-01, 2027-02-01). Older entries corresponding to Revision: v3.5.4 and dates like 2025-05-15 and 2025-05-14 were removed from the study record dates.SummaryDifference0.3%

- Check53 days agoChange DetectedThe page now shows a new revision entry (v3.5.4) and removes the previous revision (v3.5.3), indicating a minor update to the page's revision history rather than substantive content changes.SummaryDifference0.1%

- Check75 days agoChange DetectedThe page’s interface release/version stamp is updated from **Revision: v3.5.2** to **Revision: v3.5.3**, indicating a software/template update without changing the underlying trial information.SummaryDifference0.1%

Stay in the know with updates to IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.